Aller au contenu principal

Oxydative stress and ER stress in RyR1-related myopathies

Stage Master 2 - Equipe "Myologie Cellulaire et Pathologies"

Stage / Eq I.Marty

Objectifs

The project aims at a better understanding of the mechanism of action of antioxidant and inhibitor of ER stress treatments in RyR1-related myopathies.

Résumé

RyR1-related disorders (RyR1-RD) represent the most common congenital myopathies, with a severity ranging from generalized muscle weakness to perinatal lethality, with a possible neurological involvement, and are due to mutations in the RYR1 gene encoding the main intracellular calcium channel of skeletal muscle also expressed in some neurons. Due to its large size, the huge number of mutations in the RYR1 gene and the restricted number of patients, therapeutic approaches are limited up to now to physical therapy. Our group has produced and characterized a mouse model (so called RyR1-Rec) in which a muscle specific reduction in the RyR1 expression induces the apparition of a progressive myopathy mimicking the patients' disease. In preliminary studies, we evaluated antioxidants and endoplasmic reticulum (ER) stress inhibitors as potential therapeutic agents and assessed their effects on muscle strength in this mouse model. The project aims to gain a better understanding of the mechanisms of action of these two classes of compounds in the RyR1-Rec model, with the ultimate goal of identifying more effective therapeutic candidates for the treatment of RyR1-RD.

Méthodes

Primary muscle cell culture, immuno-fluorescence, western blot, RTqPCR, biochemical assays, functional assay (calcium imaging....).

Références

Tourel A, Reynaud-Dulaurier R, Brocard J, Fauré J, Marty I, Petiot A. RyR1 Is Involved in the Control of Myogenesis. Cells. 2025 Jan 21;14(3):158. doi: 10.3390/cells14030158.

Beaufils M, Melka M, Brocard J, Benoit C, Debbah N, Mamchaoui K, Romero NB, Dalmas-Laurent AF, Quijano-Roy S, Fauré J, Rendu J, Marty I. Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation. Mol Ther Nucleic Acids. 2024 Jun 17;35(3):102259. doi: 10.1016/j.omtn.2024.102259.

Pelletier L, Petiot A, Brocard J, Giannesini B, Giovannini D, Sanchez C, Travard L, Chivet M, Beaufils M, Kutchukian C, Bendahan D, Metzger D, Franzini Armstrong C, Romero NB, Rendu J, Jacquemond V, Fauré J, Marty I. In vivo RyR1 reduction in muscle triggers a core-like myopathy. Acta Neuropathol Commun. 2020 Nov 11;8(1):192. doi: 10.1186/s40478-020-01068
 

Domaines d'expertise requis

Interest in cell biology and in deciphering physio-pathological mechanisms.

Contact

Anne Petiot
Email: anne.petiotatuniv-grenoble-alpes.fr (anne[dot]petiot[at]univ-grenoble-alpes[dot]fr)

Téléchargement

Offre de stage M2 2026-2027 (PDF, 161.71 Ko)

Contacts

Pour les stages (master, licence, 3ème), envoyer directement un email au responsable de l'équipe que vous avez identifiée.

Pour une candidature spontanée pour un emploi, utilisez le formulaire de contact.

Publié le 16 juillet 2026

Mis à jour le 16 juillet 2026